FilingReader Intelligence
Yifan Pharmaceutical's subsidiary receives clinical trial approval
June 27, 2025 at 11:17 AM UTC•By FilingReader AI
Yifan Pharmaceutical Co., Ltd. (SZSE:002019) announced that its wholly-owned subsidiary, Yifan Pharmaceutical (Shanghai) Co., Ltd., received approval from the National Medical Products Administration (NMPA) on June 24, 2025, to conduct clinical trials for its Insulin Glargine Injection. The drug, a biosimilar, is intended for the treatment of diabetes.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
SZSE:002019•Shenzhen Stock Exchange
News Alerts
Get instant email alerts when Yifan Pharmaceutical publishes news
Free account required • Unsubscribe anytime